The global gallbladder cancer therapeutics market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). The major factors that are fuelling the market growth include an increase in the incidence of gall bladder polyps, chronic inflammation, and cholelithiasis, which raise the risk of developing gallbladder cancer, resulting in the rising demand for gallbladder cancer therapeutics. 

A gallbladder is a small, pear-shaped organ located on the right side of the abdomen, just beneath the liver in the human body. It stores bile produced by the liver. Gallbladder cancer is a highly uncommon disease. Gallbladder cancer is extremely difficult to diagnose, as it often exhibits no specific symptoms. Gallbladder cancer symptoms may include nausea, abdominal pain (particularly, pain in the upper right portion of the abdomen), losing weight without trying, abdominal bloating, fever, and yellowing of the skin and whites of the eyes (jaundice).

The global gallbladder cancer therapeutics market analysis includes some of the key market players such as Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Pfizer Inc., and Bristol-Myers Squibb Co. To maintain a strong position in the market, the market players are adopting various strategic moves, such as product launches, partnerships, collaborations, and mergers and acquisitions. For instance, in November 2019, Ferring launched a new company FerGene, with a focus on the global development and US commercialization of nadofaragene firadenovec, for high-grade, Bacillus Calmette-Guérin unresponsive, non-muscle-invasive bladder cancer patients. Blackstone Life Sciences will invest $400 million and their expertise to accelerate the future development and commercialization of nadofaragene firadenovec, investigational gene therapy for bladder cancer patients. 

Market Coverage

• The market number available for – 2020-2027
• Base year- 2020
• Forecast period- 2021-2027
• Segment Covered
• Regions Covered- Globally

Competitive Landscape: Sanofi S.A., F. Hoffmann-La Roche AG, Eli Lilly and Co., Pfizer Inc., and Bristol-Myers Squibb Co.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominates the market in base year?
• Which segment and region will project fastest growth in the market?
• How COVID-19 impacted the market?

o Recovery Timeline

o Deviation from pre-COVID forecast

o Most affected region and segment

• Who is the leader in the market?
• How players are addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Gallbladder Cancer Therapeutics Market Report Segmentation

By Product

• Combination Therapy

• Monotherapy

By Distribution Channel

• Hospital Pharmacies

• Retail Pharmacies

• Others

Global Gallbladder Cancer Therapeutics Market by Region